2021
DOI: 10.3390/molecules26165094
|View full text |Cite
|
Sign up to set email alerts
|

Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats

Abstract: Atherosclerosis is the main cause of cardiovascular diseases which in turn, lead to the highest number of mortalities globally. This pathophysiological condition is developed due to a constant elevated level of plasma cholesterols. Statin is currently the widely used treatment in reducing the level of cholesterols, however, it may cause adverse side effects. Therefore, there is an urgent need to search for new alternative treatment. PCSK9 is an enzyme responsible in directing LDL-receptor (LDL-R)/LDL-cholester… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 76 publications
0
2
0
Order By: Relevance
“…During the preliminary screening, ten enhance fractions (Fraction 1–10) obtained through the process described in Section 4.1 were tested using gene reporter assay (Dual-Glo Luciferase Assay, Promega) to determine the effects of A. planci on the transcriptional activity of PCSK9 promoter. Fraction 2 produced the lowest reduction in PCSK9 promoter activity to 20% of control at 6.25 μg/mL among the ten fractions [ 35 ]. In addition, after preliminary screening, the further fractionation of Fraction 2 using column chromatography revealed the presence of a major compound that, upon nuclear magnetic resonance (NMR) analysis, was identified as deoxythymidine [ 35 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…During the preliminary screening, ten enhance fractions (Fraction 1–10) obtained through the process described in Section 4.1 were tested using gene reporter assay (Dual-Glo Luciferase Assay, Promega) to determine the effects of A. planci on the transcriptional activity of PCSK9 promoter. Fraction 2 produced the lowest reduction in PCSK9 promoter activity to 20% of control at 6.25 μg/mL among the ten fractions [ 35 ]. In addition, after preliminary screening, the further fractionation of Fraction 2 using column chromatography revealed the presence of a major compound that, upon nuclear magnetic resonance (NMR) analysis, was identified as deoxythymidine [ 35 ].…”
Section: Resultsmentioning
confidence: 99%
“…Fraction 2 produced the lowest reduction in PCSK9 promoter activity to 20% of control at 6.25 μg/mL among the ten fractions [ 35 ]. In addition, after preliminary screening, the further fractionation of Fraction 2 using column chromatography revealed the presence of a major compound that, upon nuclear magnetic resonance (NMR) analysis, was identified as deoxythymidine [ 35 ]. Therefore, Fraction 2 (selected fraction) was used for further studies presented in this study.…”
Section: Resultsmentioning
confidence: 99%